ALPHAMAB-B(09966): JSKN022 IND application officially accepted by CDE.

ALPHAMAB-B (09966) announced that the company's independently developed programmatic death ligand 1 (PD-L1)/integrin v6 bispecific antibody-drug conjugate (ADC) JSKN022 has officially been accepted for clinical trial application by the China National Medical Products Administration's Drug Evaluation Center (CDE). The company plans to conduct the first human clinical study of JSKN022 for the treatment of advanced malignant solid tumors. Currently, there are no ADCs targeting integrin v6 or PD-L1 on the market worldwide, and related investigational drugs are still in the clinical research phase. Preclinical data shows that JSKN022 has anti-tumor activity against tumor cells expressing integrin v6 and/or PD-L1 in both in vitro and in vivo models. It is expected to provide new treatment options for patients with tumors resistant to PD-1/PD-L1 inhibitors or those with treatment-resistant tumors such as non-small cell lung cancer, head and neck squamous cell carcinoma, and colorectal cancer.